SPC464
Rósanólixisúmab
Status:
VeittApplication date:
26.4.2024Application published:
15.5.2024Grant published:
15.12.2025
Max expiry date:
12.5.2038Medicine name:
RystiggoMedicine for children:
No
Timeline
Today
26.4.2024Application
15.5.2024Publication
15.12.2025Registration
12.5.2038Expires
Marketing license
IS authorization number:
EU/1/23/1780Date:
10.1.2024
Foreign authorization number:
EU/1/23/1780Date:
5.1.2024
Owner
Name:
UCB Biopharma SRLAddress:
Allé de la Recherche 60, 1070 Brussels BE
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP2850101
Deadlines
TypeDeadline until
Type: Frestur til að fara yfir drög að vottorði
Deadline until: 22.11.2025